Arbejdsmarkedets Tillaegspension Buys Shares of 191,826 Abbott Laboratories $ABT

Arbejdsmarkedets Tillaegspension bought a new stake in Abbott Laboratories (NYSE:ABT) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 191,826 shares of the healthcare product maker’s stock, valued at approximately $24,034,000.

A number of other institutional investors also recently bought and sold shares of ABT. Harbor Capital Advisors Inc. bought a new position in Abbott Laboratories in the fourth quarter valued at about $27,000. Cloud Capital Management LLC purchased a new stake in Abbott Laboratories in the 3rd quarter worth approximately $29,000. Guerra Advisors Inc purchased a new stake in Abbott Laboratories in the 3rd quarter worth approximately $31,000. Bridge Generations Wealth Management LLC purchased a new stake in Abbott Laboratories in the 3rd quarter worth approximately $33,000. Finally, Copia Wealth Management purchased a new stake in Abbott Laboratories in the 3rd quarter worth approximately $38,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

Shares of Abbott Laboratories stock opened at $84.80 on Friday. The stock has a market cap of $147.70 billion, a price-to-earnings ratio of 23.75, a price-to-earnings-growth ratio of 1.40 and a beta of 0.65. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The stock has a 50 day moving average price of $99.59 and a 200-day moving average price of $113.55. Abbott Laboratories has a one year low of $81.97 and a one year high of $139.06.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts expect that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.0%. Abbott Laboratories’s payout ratio is 70.59%.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: TipRanks highlighted Abbott as one of three “Strong Buy” Dividend Aristocrat stocks, which can support the stock’s appeal for income-focused investors despite a high payout ratio. 3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26
• Neutral Sentiment: Jim Cramer called Abbott one of the “greatest American companies” while comparing the selloff to the 1999 market backdrop, a comment that may help sentiment but does not change fundamentals. Jim Cramer Compares the Current Selloff in Abbott Labs to the 1999 Market Environment
• Neutral Sentiment: Recent insider-trading coverage noted buying activity around Abbott, which can be viewed as a modest confidence signal but is not necessarily a major catalyst on its own. Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell (ABT)
• Negative Sentiment: Investor concerns remain centered on Abbott’s post-earnings weakness, with commentary pointing to Exact Sciences dilution, legal risks, and softer Diagnostics trends as reasons the shares have been pressured. Abbott Stock at 52-Week Low After Q1 Earnings: Book Profits or Hold?

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Royal Bank Of Canada reduced their target price on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating for the company in a report on Friday, April 17th. UBS Group cut their target price on Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating for the company in a research report on Monday, April 20th. Benchmark cut their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Piper Sandler cut their target price on Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Finally, Bank of America cut their target price on Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $119.43.

Insider Transactions at Abbott Laboratories

In other news, EVP Mary K. Moreland sold 613 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the transaction, the executive vice president owned 104,291 shares in the company, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Eric Shroff sold 709 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $81,946.22. Following the sale, the senior vice president directly owned 39,164 shares of the company’s stock, valued at $4,526,575.12. This represents a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.